Last reviewed · How we verify
Aripiprazole or Perphenazine
Aripiprazole is a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A partial agonist that modulates dopaminergic and serotonergic neurotransmission; perphenazine is a typical antipsychotic that blocks dopamine D2 receptors.
Aripiprazole is a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A partial agonist that modulates dopaminergic and serotonergic neurotransmission; perphenazine is a typical antipsychotic that blocks dopamine D2 receptors. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment with aripiprazole).
At a glance
| Generic name | Aripiprazole or Perphenazine |
|---|---|
| Also known as | Abilify, Trilafon |
| Sponsor | Johns Hopkins University |
| Drug class | Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine) |
| Target | Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); Dopamine D2 receptor (perphenazine) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Aripiprazole's partial agonist activity at dopamine receptors provides stabilization of dopaminergic signaling, reducing both excessive and insufficient dopamine activity. Perphenazine acts as a dopamine antagonist to reduce psychotic symptoms. Both drugs are used in psychiatric conditions where dopaminergic dysregulation contributes to symptomatology.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute manic or mixed episodes)
- Major depressive disorder (adjunctive treatment with aripiprazole)
- Irritability associated with autism spectrum disorder (aripiprazole)
Common side effects
- Akathisia
- Headache
- Anxiety
- Insomnia
- Nausea
- Tremor
- Weight gain
- Extrapyramidal symptoms
Key clinical trials
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Reducing Antipsychotic-Induced Weight Gain in Children With Metformin (PHASE1)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (PHASE4)
- Antipsychotics and Risk of Hyperglycemic Emergencies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole or Perphenazine CI brief — competitive landscape report
- Aripiprazole or Perphenazine updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI